Does stroke etiology influence outcome in the posterior circulation? An analysis of 107 consecutive acute basilar occlusion thrombectomies

Roberta K. Sefcik, MD, Daniel A. Tonetti, MD, Shashvat M. Desai, MD, Stephanie M. Casillo, BS, Michael J. Lang, MD, Ashutosh P. Jadhav, MD, PhD, and Bradley A. Gross, MD

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

OBJECTIVE Acute basilar artery occlusion (BAO) harbors a more guarded prognosis after thrombectomy compared with anterior circulation large-vessel occlusion. Whether this is a function of a greater proportion of atherosclerotic/intrinsic lesions is not well studied. The authors aimed to elucidate the prevalence and predictors of intracranial intrinsic atherosclerotic disease in patients with acute BAO and to compare angiographic and clinical outcomes between patients with BAO secondary to embolic versus intrinsic disease.

METHODS A prospectively maintained stroke database was reviewed for all patients presenting between January 2013 and December 2019 to a tertiary care academic comprehensive stroke center with acute, nontandem BAO. Patient data were extracted, subdivided by stroke mechanism and treatment modality (embolic [thrombectomy only] and intrinsic [thrombectomy + stenting]), and angiographic and clinical results were compared.

RESULTS Of 107 patients, 83 (78%) had embolic occlusions (thrombectomy only) and 24 (22%) had intrinsic disease (thrombectomy + stenting). There was no significant difference in patient age, presenting National Institutes of Health Stroke Scale score, time to presentation, selected medical comorbidities (hypertension, hyperlipidemia, diabetes, and atrial fibrillation), prior stroke, and posterior circulation Alberta Stroke Program Early CT Score. Patients with intrinsic disease were more likely to be active smokers (50% vs 26%, \( p = 0.04 \)) and more likely to be male (88% vs 48%, \( p = 0.001 \)). Successful recanalization, defined as a modified Thrombolysis in Cerebral Infarction (mTICI) grade of 2b or 3, was achieved in 90% of patients and did not differ significantly between the embolic versus intrinsic groups (89% vs 92%, \( p > 0.99 \)). A 90-day good outcome (modified Rankin Scale [mRS] score 0–2) was found in 37% of patients overall and did not differ significantly between the two groups (36% vs 41%, \( p = 0.41 \)). Mortality was 40% overall and did not significantly differ between groups (41% vs 36%, \( p = 0.45 \)).

CONCLUSIONS In the current study, demographic and clinical results for acute BAO showed that compared with intrinsic disease, thromboembolic disease is a more common mechanism of acute BAO, with 78% of patients undergoing thrombectomy alone. However, there was no significant difference in revascularization and outcome results between patients with embolic disease and those with intrinsic disease.

https://thejns.org/doi/abs/10.3171/2021.4.FOCUS2189

KEYWORDS reperfusion; stroke; thrombectomy; stent; atherosclerosis

Endovascular therapy (EVT) for anterior circulation large-vessel occlusion (LVO) is supported by class 1 evidence. Despite a lack of class 1 evidence, EVT for BAO is widely practiced and several clinical trials have evaluated the benefit of EVT for BAO in a prospective manner. Given the differences in the underlying mechanism of BAO between embolic and intrinsic atherosclerosis, endovascular management strategies addressing these contrasting pathologies differ. Treatment of residual basilar stenosis after

ABBREVIATIONS BAO = basilar artery occlusion; EVT = endovascular therapy; IV tPA = intravenous tissue plasminogen activator; LVO = large-vessel occlusion; mRS = modified Rankin Scale; mTICI = modified Thrombolysis in Cerebral Infarction; NIHSS = National Institutes of Health Stroke Scale; pc-ASPECTS = posterior circulation Alberta Stroke Program Early CT Score.

SUBMITTED February 6, 2021. ACCEPTED April 12, 2021.

INCLUDE WHEN CITING DOI: 10.3171/2021.4.FOCUS2189.
thrombectomy necessitating the deployment of permanent stents with or without angioplasty has been previously described as a treatment for basilar atherosclerosis.\textsuperscript{5–18}

It remains unknown whether there are predictors of intrinsic atherosclerotic disease underlying an acute BAO. Knowledge of predictors of intrinsic atherosclerotic disease that requires intracranial stenting for vessel recanalization may allow for hastened reperfusion in patients with acute BAO. The purpose of this study was to 1) elucidate the prevalence and predictors of intracranial intrinsic atherosclerotic disease in patients with acute BAO in a North American cohort, and 2) compare angiographic and clinical outcomes between patients with BAO secondary to embolic versus intrinsic disease.

Methods

A retrospective analysis of prospectively collected data was performed for all patients presenting to a tertiary care academic comprehensive stroke center with posterior circulation acute ischemic stroke between January 2013 and December 2019. Demographic characteristics, clinical and radiological data, and treatment and procedural information were extracted and analyzed. This study was approved by the local institutional review board.

Patient Selection

Patients with acute ischemic stroke who presented to a single comprehensive stroke center and underwent thrombectomy for a BAO during the study period were analyzed. Occlusion location was confirmed by CTA, MRA, and/or cerebral angiography. Patients were excluded if the occlusion was distal to the basilar artery (e.g., of the posterior cerebral artery) or in the case of tandem lesions (vertebral ostial occlusion and concomitant BAO).

Procedural Technique

The manual aspiration thrombectomy procedure was performed at one of two comprehensive stroke centers affiliated with a large academic institution by one of four neurointerventionalists. Briefly, the cervical vasculature (typically V\textsubscript{2}) was catheterized using standard techniques with a long 6-Fr sheath. After an LVO was confirmed via base catheter fluoroscopy, a triaxial system comprising an aspiration catheter, a microcatheter, and a microwire was advanced through the thrombus. The aspiration catheter was advanced to the face of the thrombus, and the microcatheter and wire were removed. Manual aspiration was applied via syringe, which was subsequently withdrawn slowly under continuous aspiration. The 6-Fr long sheath was then aspirated to remove any additional thrombus.

If the basilar artery remained flow limited because of stenosis secondary to a presumed atherosclerotic plaque, a stentriever (Solitaire, Stryker Neurovascular) was deployed over the lesion and a run was performed with the stentriever deployed (Fig. 1). This run was utilized to measure the basilar artery diameters on both sides of the lesion, and an appropriately sized balloon-mounted coronary stent (Multi-Link Vision Coronary Stent System, Abbott Vascular; or Integrity Coronary Stent System, Medtronic) was selected. Patients were administered a weight-based loading dose of intravenous eptifibatide. A 115-cm Catalyst 5 (Stryker Neurovascular) catheter or, in less recent cases, a 115-cm 058 Navien (Medtronic) catheter was guided through the 6-Fr sheath over the microcatheter-microwire to the plaque, and the stent was deployed through the intermediate catheter over the microwire. A poststen run was then performed. After the procedure, patients were administered rectal aspirin on the angiogram table followed by a clopidogrel load once CT had confirmed no hemorrhagic complication. In all cases, a modified Thrombolysis in Cerebral Infarction (mTICI) grade was assigned according to the original TICI classification,\textsuperscript{19} with an mTICI grade of 2b representing a reperfusion of at least two-thirds of the vascular territory affected.

Study Variables

Baseline demographics (age, sex), clinical (stroke severity, time from symptom onset, risk factor/medical history profile) and radiographic (posterior circulation Alberta Stroke Program Early CT Score [pc-ASPECTS], occlusion location) characteristics, adjunctive intravenous tissue plasminogen activator (IV tPA) information, and procedural technique and result (mTICI grade) were collected and analyzed. In addition to mTICI grade, outcome variables included early recovery, early deterioration, postoperative hemorrhage, and outcome as defined by the mRS score at 90 days.

Stratified Analysis

Patients were stratified by the procedure required to achieve revascularization. Patients who underwent thrombectomy only were compared with those who required stenting and/or angioplasty due to flow-limiting atherosclerotic disease, and their demographics and outcomes were analyzed and compared, including the revascularization result (mTICI grade) and the clinical outcome (90-day mRS score and mortality).

Statistical Analysis

Statistical analysis was performed using IBM SPSS Statistics version 23 (IBM Corp.). Univariate analyses were performed using analysis of variance for continuous variables and the Pearson chi-square test for categorical variables. Multivariate logistic regression analysis was
subsequently performed to identify independent predictors of 90-day outcomes. Outcome measures, including final reperfusion, mRS score at 90 days, mortality, and complications, were directly compared using the Pearson chi-square test.

### Results

#### Patient Demographics

A total of 107 patients with acute ischemic stroke due to nontandem BAO underwent endovascular treatment during the study period. Five additional patients with tandem vertebral ostial disease were excluded from the analysis. Eighty-three patients (78%) underwent thrombectomy only, and 24 patients (22%) underwent thrombectomy in combination with basilar artery stenting during the study period. The mean patient age was 64.5 years with a standard deviation ± 16.8 years, and 57% of patients were male (Table 1). The mean National Institutes of Health Stroke Scale (NIHSS) score at hospital presentation was 18.7 ± 9.3. The mean pc-ASPECTS was 9.0 ± 1.3, and 18.2% of patients received IV tPA.

Compared with patients treated with thrombectomy alone, those requiring stenting were more likely to be male (88% vs 48%, p = 0.001) and were more frequently tobacco smokers (50% vs 26%, p = 0.038). There was otherwise no significant difference between the two patient groups in age, presenting NIHSS score, when the patient was last known to be well, medical comorbidities, pc-ASPECTS, or IV tPA administration.

### Outcomes

An mTICI reperfusion grade ≥ 2b was achieved in 90% of patients overall; this was not significantly different between the groups (Table 2). Fifty-one percent of the patients had early clinical recovery, and 9% experienced deterioration; these rates did not significantly differ between the two groups. Postprocedural hemorrhage was seen in 6% of patients, which also did not significantly differ between the two groups. There were no cases of acute stent reoclusion. Overall, an mRS score of 0–2 at 90 days was achieved in 37% of patients and 40% of patients died, with no significant difference in either outcome between the two groups.

Multivariate analysis was performed to determine predictors of outcome. After controlling for male sex, time to presentation, smoking status, pc-ASPECTS, and stent use, there were no independent predictors of functional outcome (mRS score 0–2) at 90 days or 90-day mortality.

### Discussion

The guarded prognosis for acute vertebrobasilar oc-

---

**TABLE 1. Overall baseline characteristics**

<table>
<thead>
<tr>
<th></th>
<th>All Patients</th>
<th>Thrombectomy Only</th>
<th>Thrombectomy + Stenting</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>107</td>
<td>83</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Mean age, yrs</td>
<td>64.5 ± 16.8</td>
<td>65.3 ± 17.3</td>
<td>62.4 ± 14.8</td>
<td>0.479</td>
</tr>
<tr>
<td>Male sex</td>
<td>61 (57)</td>
<td>40 (48.2)</td>
<td>21 (87.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mean NIHSS score</td>
<td>18.7 ± 9.3</td>
<td>19.1 ± 9.2</td>
<td>17.3 ± 9.6</td>
<td>0.416</td>
</tr>
<tr>
<td>Mean last known well to arrival, hrs</td>
<td>13.5 ± 17.3</td>
<td>12.1 ± 16.1</td>
<td>18.6 ± 20.4</td>
<td>0.138</td>
</tr>
<tr>
<td>Hypertension</td>
<td>80/103 (77.7)</td>
<td>61/79 (77.2)</td>
<td>19/24 (79.2)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>48/103 (46.6)</td>
<td>36/79 (45.6)</td>
<td>12/24 (50)</td>
<td>0.816</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>24/98 (24.5)</td>
<td>20/76 (26.3)</td>
<td>4/22 (18.2)</td>
<td>0.577</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>28/99 (28.3)</td>
<td>24/78 (30.8)</td>
<td>4/21 (19)</td>
<td>0.415</td>
</tr>
<tr>
<td>Smoking</td>
<td>31/100 (31)</td>
<td>20/78 (26.5)</td>
<td>11/22 (50)</td>
<td>0.038</td>
</tr>
<tr>
<td>Prior stroke</td>
<td>22/96 (22.9)</td>
<td>15/75 (20)</td>
<td>7/21 (33.3)</td>
<td>0.242</td>
</tr>
<tr>
<td>Mean pc-ASPECTS</td>
<td>9 ± 1.3</td>
<td>9.1 ± 1.2</td>
<td>8.7 ± 1.5</td>
<td>0.157</td>
</tr>
<tr>
<td>IV tPA</td>
<td>18/99 (18.2)</td>
<td>15/77 (19.5)</td>
<td>3/22 (13.6)</td>
<td>0.756</td>
</tr>
</tbody>
</table>

Values represent the number of patients (%) unless stated otherwise. Mean values are presented as the mean ± SD.

**TABLE 2. Angiographic and clinical outcomes**

<table>
<thead>
<tr>
<th></th>
<th>All Patients</th>
<th>Thrombectomy Only</th>
<th>Thrombectomy + Stenting</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>mTICI grade ≥2b</td>
<td>96/107 (89.7)</td>
<td>74/83 (89.2)</td>
<td>22/24 (91.7)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Early clinical recovery</td>
<td>53/104 (51)</td>
<td>44/83 (53)</td>
<td>9/21 (42.9)</td>
<td>0.469</td>
</tr>
<tr>
<td>Hemorrhage on 24-hr CT</td>
<td>6/107 (5.6)</td>
<td>4/83 (4.8)</td>
<td>2/24 (8.3)</td>
<td>0.614</td>
</tr>
<tr>
<td>Early neurological deterioration</td>
<td>9/104 (8.7)</td>
<td>7/83 (8.4)</td>
<td>2/21 (9.5)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>mRS score 0–2 at 90 days</td>
<td>36/98 (36.7)</td>
<td>27/76 (35.5)</td>
<td>9/22 (40.9)</td>
<td>0.412</td>
</tr>
<tr>
<td>Mortality</td>
<td>39/98 (39.8)</td>
<td>31/76 (40.8)</td>
<td>8/22 (36.4)</td>
<td>0.454</td>
</tr>
</tbody>
</table>

Values represent the number of patients (%) unless stated otherwise.
clclusion^2 is worthy of more careful scrutiny. The finding that intrinsic disease underlies acute BAO in one-fifth of North American patients in this study begs the question of whether this is a contributing factor to worse outcomes given the added need to address the underlying lesion in addition to a standard thrombectomy.

Systematic study of vertebrobasilar thrombectomy is less prevalent in the literature compared with the more common anterior circulation LVOs. The BEST study was a trial conducted at 28 stroke centers in China that attempted to randomize patients presenting within 8 hours of symptom onset with acute vertebrobasilar occlusion who underwent EVT plus medical therapy or medical therapy alone.7 The trial was terminated early due to high crossover rates and poor recruitment. Good outcome at 90 days (mRS score 0–3) was seen in 42% of patients in the intervention group and 32% in the control group, a difference not meeting statistical significance. However, a secondary, as-treated analysis demonstrated statistically significantly greater rates of good outcome in patients who underwent endovascular treatment (47%) versus those assigned to medical therapy without crossover (24%).

**Key Results**

Our results demonstrate a good overall rate (90%) of successful reperfusion in patients with acute BAO (mTICI grade ≥2b), comparable to success rates in recent multicenter data and other intrinsic series.20,25 Notably, occlusion etiology did not influence this rate significantly. More supple intermediate catheters have made the navigation of noncompliant stents to desired intracranial target vessels far more facile,21 explaining the reasonable technical success for this approach in our study with 24 patients who underwent acute stenting. Of note, potential predictors for intrinsic lesions included male sex and smoking status.

As successful reperfusion did not significantly differ between the two patient groups, rates of 90-day good outcome, defined as an mRS score of 0–2 at 90 days, and mortality did not significantly differ either. These results are not entirely dependent, as differing stroke etiology may serve as a biomarker/predictor of overall outcome independent of reperfusion result. Periprocedural complications, particularly hemorrhagic complications, did not significantly differ between the two groups; this is a relevant finding in the context of a ubiquitous dual antiplatelet load in the intrinsic disease population and will require substantiating across a larger patient cohort. While some may advocate for administration of a glycoprotein IIb/IIA inhibitor in lieu of intracranial stenting for acute occlusion due to intrinsic disease,22 the concern for an incompletely treated intrinsic lesion bares the intuitive prospective risk of recurrent transient ischemic attack or stroke; extrapolating from the SAMMPRIS trial,23 this rate was 6% at 30 days.

**Limitations**

While our study was a prospective analysis of consecutive patients with blinded data review and good retention for 90-day follow-up, we are limited by a relatively small sample size of patients who underwent acute stenting, limiting our analysis of complications. In addition, a lack of a statistically significant difference in reperfusion and good outcome rates may be overcome by a larger sample size. TICI recanalization grades were not blinded but rather assigned by the interventionalist posttreatment. Future multicenter analyses with blinded TICI grading would improve the robustness of this initial analysis of acute BAO in a North American population. Furthermore, patients were defined as having intrinsic or embolic disease by the revascularization procedure employed. A pretreatment radiographic definition would be superior.

**Interpretation and Generalizability**

Our results demonstrate that demographic factors may be useful in predicting the likelihood of an intrinsic lesion (male sex, smoking status). Furthermore, in contrast to the BEST trial, our North American population harbored an approximately 20% prevalence of intrinsic disease underlying acute BAO, reinforcing, as is known, that different populations harbor differing frequencies of underlying atherosclerotic occlusion; this limits the external validity of our results to these differing populations.

Our results also suggest that reperfusion is similarly feasible and safe in patients with athero-occlusive lesions with the usage of noncompliant coronary stents as compared with more typical thromboembolic occlusions requiring thrombectomy alone. Interestingly, clinical outcomes were fairly uniform across both cohorts as well. Our results differ from the current body of literature comparing posterior circulation lesions in which patients with intrinsic disease have lower recanalization rates.24,25

**Conclusions**

Thromboembolic disease was a more common mechanism of acute BAO than intrinsic disease, with 78% of patients in the current study undergoing thrombectomy alone. Intrinsic disease was seen more often in active smokers and males. Rates of successful recanalization and functional outcomes were comparable between patients with and without intrinsic disease.

**References**


Disclosures
Dr. Gross is a consultant for Medtronic and MicroVention.

Author Contributions
Conception and design: Gross, Jadhav. Acquisition of data: Gross, Sefcik, Tonetti, Desai, Casillo. Analysis and interpretation of data: Gross, Sefcik, Tonetti. Critical revision of the article: all authors.

Supplemental Information

Abstract Presentations
Portions of this study were accepted for presentation at the 2020 CNS Annual Meeting, Miami, Florida.

Correspondence
Bradley A. Gross: University of Pittsburgh Medical Center, Pittsburgh, PA. grossb2@upmc.edu.